Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 6/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4712177 | 0.98 | EPHX2 (0.39) | ALDH1A1SMN1; SMN2EPHX2GAA | |
| SCHEMBL4710638 | 0.98 | EPHX2 (0.39) | ALDH1A1SMN1; SMN2EPHX2GAA | |
| SCHEMBL2803563 | 0.94 | ALDH1A1 (0.38) | ALDH1A1SMN1; SMN2EPHX2GAA | |
| SCHEMBL15922575 | 0.88 | EPHX2 (0.33) | EPHX2 | |
| SCHEMBL15922573 | 0.88 | EPHX2 (0.33) | EPHX2 | |
| SCHEMBL15923054 | 0.85 | ALDH1A1 (0.40) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL4712185 | 0.85 | ALDH1A1 (0.40) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL29078826 | 0.83 | ALDH1A1 (0.39) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL15922889 | 0.81 | GRIN2D (0.31) | ALDH1A1SMN1; SMN2EPHX2 | |
| SCHEMBL15922888 | 0.81 | GRIN2D (0.31) | ALDH1A1SMN1; SMN2EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8062829-B2 | Chemically amplified resist composition and chemically amplified resist composition for immersion lithography | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2011-11-22 | — | — | US | disclosed |
| US-20090220890-A1 | CHEMICALLY AMPLIFIED RESIST COMPOSITION AND CHEMICALLY AMPLIFIED RESIST COMPOSITION FOR IMMERSION LITHOGRAPHY | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2009-09-03 | — | — | US | disclosed |
| EP-1398309-B1 | NOVEL ADAMANTANE DERIVATIVE | IDEMITSU KOSAN CO (JP) | 2008-02-20 | — | — | EP | disclosed |
| US-6833388-B2 | 1,3-adamantanedicarboxylic acid-bis(2'-alkyl-2'-adamantyl)-esters; photoresist additive; resin heat resistance improver; pharmaceutical and agrochemical intermediates | IDEMITSU PETROCHEMICAL CO., LTD. (JP) | 2004-12-21 | — | — | US | disclosed |
| US-20040157923-A1 | Novel adamantane derivative | IDEMITSU KOSAN CO. LTD. (JP) | 2004-08-12 | — | — | US | disclosed |
| EP-1230227-B1 | BENZOXA-AND BENZOTHIAZOLYL SULFAMATES AND THEIR USE AS STEROID SULFATASE INHIBITORS | NOVARTIS AG (CH) | 2004-06-23 | — | — | EP | disclosed |
| US-6716865-B1 | SUBSTITUTED AT THE 2 POSITION; A SULFAMATE BOUND VIA OXYGEN TO THE PHENYL PART OF THE RING STRUCTURE; SULFAMOYLATION; STEROID SULFATASE INHIBITOR, ACNE | NOVARTIS AG (CH) | 2004-04-06 | — | — | US | disclosed |
| EP-1398309-A1 | NOVEL ADAMANTANE DERIVATIVE | IDEMITSU PETROCHEMICAL CO., LTD. (JP) | 2004-03-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040157923-A1 | Novel adamantane derivative | TAS1R1, TAS2R1, ADORA1 | ALDH1A1 225/4885SMN1; SMN2 3427/4885EPHX2 2876/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.